Results 81 to 90 of about 5,702,542 (372)
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
Nature Communications, 2020 CD229 is expressed on the surface of multiple myeloma cells, as well as B and T lymphocytes. Here, the authors engineer CD229-specific CAR T cells and, using patient samples and mouse models, show that treatment with these cells reduces tumour burden and
Sabarinath V. Radhakrishnan +13 more
doaj +1 more source
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
Blood Cancer Journal, 2023 Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress.
Keiji Kurata +28 more
doaj +1 more source
Bispecific antibodies in multiple myeloma treatment: A journey in progress
Frontiers in Oncology, 2022 The incorporation of novel agents and monoclonal antibody-based therapies into the treatment of multiple myeloma (MM) has significantly improved long-term patient survival.
Shih-Feng Cho +5 more
doaj +1 more source
Dissecting racial disparities in multiple myeloma
Blood Cancer Journal, 2020 Multiple myeloma (MM) is a fatal plasma cell dyscrasia with a median overall survival of 5 to 10 years. MM progresses from the more common but often subclinical precursor states of monoclonal gammopathy of undetermined significance (MGUS), and smoldering
Catherine R. Marinac +4 more
semanticscholar +1 more source
Identification of inhibitors of the Salmonella FraB deglycase, a drug target
FEBS Open Bio, EarlyView.A high‐throughput screen was used to identify inhibitors of Salmonella FraB, a drug target. Characterization of top hits (identified after an additional counter screen) revealed that some triazolidines, thiadiazolidines, and triazolothiadiazoles are mixed‐type inhibitors of FraB.
Jamison D. Law +6 more
wiley +1 more source
Emerging immunotherapies in multiple myeloma
British medical journal, 2020 Despite considerable advances in treatment approaches in the past two decades, multiple myeloma remains an incurable disease. Treatments for myeloma continue to evolve with many emerging immunotherapies.
U. Shah, S. Mailankody
semanticscholar +1 more source
Possible role of human ribonuclease dicer in the regulation of R loops
FEBS Open Bio, EarlyView.R loops play an important role in regulating key cellular processes such as replication, transcription, centromere stabilization, or control of telomere length. However, the unscheduled accumulation of R loops can cause many diseases, including cancer, and neurodegenerative or inflammatory disorders. Interestingly, accumulating data indicate a possible
Klaudia Wojcik +2 more
wiley +1 more source
Molecular Cancer Therapeutics, 2020 Multiple myeloma is a plasma cell malignancy, which grows in the bone marrow (BM). The major population of cells in the BM is represented by neutrophils and they can form neutrophil extracellular traps (NET).
Marina Li +7 more
semanticscholar +1 more source
Bone‐wise rigid registration of femur, tibia, and fibula for the tracking of temporal changes
Journal of Applied Clinical Medical Physics, EarlyView.Abstract Background Multiple myeloma (MM) induces temporal alterations in bone structure, such as osteolytic bone lesions, which are challenging to identify through manual image interpretation. The large variation in radiologists' assessments, even at expert centers, further complicates diagnosis.
Arttu Ruohola +5 more
wiley +1 more source
Molecular and cellular paradigms of multidrug resistance in cancer
Cancer Reports, Volume 5, Issue 12, December 2022., 2022 Abstract Background The acquisition of resistance to chemotherapy is a major hurdle in the successful application of cancer therapy. Several anticancer approaches, including chemotherapies, radiotherapy, surgery and targeted therapies are being employed for the treatment of cancer.
Foram U. Vaidya +6 more
wiley +1 more source